Risk for Depression During Interferon-Alpha Treatment Is Affected by the Serotonin Transporter Polymorphism

Biological Psychiatry

Volumn 65, Issue 4, 2009, Pages 344-348

  Lotrich, Francis E ^a   Ferrell, Robert E ^b   Rabinovitz, Mordechai ^a   Pollock, Bruce G ^a,c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cytokine; depression; interferon; polymorphism; prospective; serotonin

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2; RIBAVIRIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN POLYMORPHISM; TANDEM REPEAT;

ALLELES; ANTIVIRAL AGENTS; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER, MAJOR; DNA; FEMALE; HEPATITIS C; HUMANS; INTERFERON TYPE I, RECOMBINANT; MALE; MIDDLE AGED; NEUROTIC DISORDERS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SLEEP;

EID: 58349101061     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2008.08.009     Document Type: Article

References (51)

1. Stoudemire A., Frank R., Hedemark N., Kamlet M., and Blazer D.G. The economic burden of depression. Gen Hosp Psychiatry 8 (1986) 387-394
2. Merikangas K.R., Chakravarti A., Moldin S.O., Araj H., Blangero J., Burmeister M., et al. Future of genetics of mood disorders research. Biol Psychiatry 52 (2002) 457-477
3. Schuckit M.A., Tipp J.E., Bucholz K.K., Nurnberger J.I.J., Hesselbrock V.M., Crowe R.R., et al. The life-time rates of three major mood disorders and four major anxiety disorders in alcoholics and controls. Addiction 92 (1997) 1289-1304
4. Blazer D.G. Mood disorders: Epidemiology. In: Sadock B.J., and Sadock V.A. (Eds). Comprehensive Textbook of Psychiatry, 7th ed (2000), Williams & Williams, Philadelphia: Lippincott 1298-1307
5. Lotrich F.E., and Pollock B.G. Meta-analysis of serotonin transporter polymorphisms and affective disorder. Psychiatr Genet 14 (2004) 121
6. Hoefgen B., Schulze T.G., Ohlraun S., von Widdern O., Hofels S., Gross M., et al. The power of sample size and homogenous sampling: Association between the 5-HTTLPR serotonin transporter polymorphism and major depressive disorder. Biol Psychiatry 57 (2005) 247-251
7. Zalsman G., Huang Y., Oquendo M.A., Burke A.K., Hu X., Brent D.A., et al. Association of a triallelic serotonin transporter gene promoter region (5-HTTLPR) polymorphism with stressful life events and severity of depression. Am J Psychiatry 163 (2006) 1588-1593
8. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., et al. Influence of life stress on depression: Moderation by a polymorphism in the 5-HTT gene. Science 301 (2003) 368-389
9. Kendler K.S., Kuhn J.W., Vittum J., Prescott C.A., and Riley B. The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: A replication. Arch Gen Psychiatry 62 (2005) 529-535
10. Chipman P., Jorm A.F., Prior M., Sanson A., Smart D., Tan X., et al. No interaction between the serotonin transporter polymorphism (5-HTTLPR) and childhood adversity or recent stressful life events on symptoms of depression: Results from two community surveys. Am J Med Genet B Neuropsychiatr Genet 144 (2007) 561-565
11. Malaguarnera M., Laurino A., Di Fazio I., Pistone G., Castorina M., Guccione N., et al. Neuropsychiatric effects and type of IFN-a in chronic hepatitis C. J Interferon Cytokine Res 21 (2001) 273-278
12. Lotrich F.E., Rabinovitz F., Gironda P., and Pollock B.G. Depression following pegylated interferon-alpha: Characteristics and vulnerability. J Psychosom Res 63 (2007) 131-135
13. Trask P.C., Esper P., Riba M., and Redman B. Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 18 (2000) 2316-2326
14. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioral effects of interferon-a in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002) 643-652
15. Capuron L., and Miller A.H. Cytokines and psychopathology: Lessons from interferon-a. Biol Psychiatry 56 (2004) 819-908
16. Raison C.L., Demetrashvili M., Capuron L., and Miller A.H. Neuropsychiatric adverse effects of interferon-a: Recognition and management. CNS Drugs 19 (2005) 105-123
17. Maes M. Evidence for an immune response in major depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19 (1995) 11-38
18. Rothermundt M., Arolt V., Fenker J., Gutbrodt H., Peters M., and Kirchner H. Different immune patterns in melancholic and non-melancholic major depression. Eur Arch Psychiatry Clin Neurosci 251 (2001) 90-97
19. Danese A., Moffitt T.E., Pariante C.M., Ambler A., Poulton R., and Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 65 (2008) 409-415
20. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., et al. Prefrontal cortical hypometabolism during low-dose inteferon alpha treatment. Psychopharmacology (Berl) 152 (2001) 383-389
21. Capuron L., Pagnoni G., Demetrashvili M., Woolwine B.J., Nemeroff C.B., Berns G.S., et al. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol Psychiatry 58 (2005) 190-196
22. Wang J., Campbell I.L., and Zhang H. Systemic interferon-regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry 13 (2008) 293-302
23. Geiss G.K., Carter V.S., He Y., Kwieciszewski B.K., Holzman T., Korth M.J., et al. Gene expression profiling of the cellular transcriptional network regulated by alpha/beta interferon and its partial attenuation by the hepatitis C virus nonstructural 5A protein. J Virol 77 (2003) 6367-6375
24. Shuto H., Kataoka Y., Horikawa T., Fujihara N., and Oishi R. Repeated interferon-a administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747 (1997) 348-351
25. Liu Y., and Samuel C.E. Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. J Biol Chem 274 (1999) 5070-5077
26. Muller N., and Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: Towards an integrated view of depression. Mol Psychiatry 12 (2007) 988-1000
27. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., et al. Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
28. Abe S., Hori T., Suzuki T., Baba A., Shiraishi H., and Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 24 (1999) 359-363
29. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., et al. Interferon-alpha-induced changes in tryptophan metabolism: Relationship to depression and paroxetine treatment. Biol Psychiatry 54 (2003) 906-914
30. Dunn A.L., and Crnic L.S. Repeated injections of interferon-alpha A/D in Balb/c mice: Behavioral effects. Brain Behav Immun 7 (1993) 104-111
31. Wichers M.C., and Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 29 (2004) 11-17
32. Heils A., Mossner R., and Lesch K.P. The human serotonin transporter gene polymorphism-basic research and clinical implication. J Neural Transm 104 (1997) 1005-1014
33. Lee M., Bailer U.F., Frank G.K., Henry S.E., Meltzer C.C., Price J.C., et al. Relationship of a 5-HT transporter functional polymorphism to 5-HT1A receptor binding in healthy women. Mol Psychiatry 10 (2005) 715-716
34. Hariri A.R., Drabant E.M., Munoz K.E., Kolachana B.S., Mattay V.S., Egan M.F., et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62 (2005) 146-152
35. Pezawas L., Meyer-Lindenberg A., Drabant E.M., Verchinski B.A., Munoz K.E., Kolachana B.S., et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: A genetic susceptibility mechanism for depression. Nat Neurosci 8 (2005) 828-834
36. Hu X., Lipsky R., Zhu G., Akhtar L., Taubman J., Greenberg D., et al. Serotonin transporter promoter gain of function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 78 (2006) 815-826
37. Kaiser R., Muller-Oerlinghausen B., Filler D., Tremblay P., Berghofer A., Roots I., et al. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am J Med Genet 114 (2002) 323-328
38. Canli T., and Lesch K.P. Long story short: The serotonin transporter in emotion regulation and social cognition. Nat Neurosci 10 (2007) 1103-1109
39. Brummett B.H., Krystal A.D., Ashley-Koch A., Kuhn C.M., Zuchner S., Siegler I.C., et al. Sleep quality varies as a function of 5-HTTLPR genotype and stress. Psychosom Med 69 (2007) 621-624
40. Kendler K.S., Kuhn J., and Prescott C.A. The interrelationship of neuroticism, sex, and stressful life events in the prediction of episodes of major depression. Am J Psychiatry 161 (2004) 631-636
41. Riemann D., and Voderholzer U. Primary insomnia: A risk factor to develop depression?. J Affect Disord 76 (2003) 255-259
42. Capuron L., Ravaud A., Miller A.H., and Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18 (2004) 205-213
43. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., and Kupfer D.J. Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research. Psychiatry Res 28 (1989) 193-213
44. Costa P.T., and McCrae R.R. NEO PI-R Professional Manual (1992), Psychological Assessment Resources, Odessa, FL
45. Miller M.D., Paradis C.F., Houck P.R., Mazumdar S., Stack J.A., Rifai A.H., et al. Rating chronic medical illness burden in geropsychiatric practice and research: Application of the Cumulative Illness Rating Scale. Psychiatry Res 41 (1992) 237-248
46. Wendland J.R., Martin B.J., Kruse M.R., Lesch K.P., and Murphy D.L. Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531. Mol Psychiatry 11 (2006) 224-226
47. Uher R., and McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: Review and methodological analysis. Mol Psychiatry 13 (2008) 131-146
48. Kraus M.R., Al-Taie O., Schefer A., Pfersdorff M., Lesch K.P., and Scheurlen M. Serotonin-1A receptor gene (HTR1A) vairation predicts interferon-induced depression chronic hepatitis C. Gastroenterology 132 (2007) 1279-1286
49. Morikawa O., Sakai N., Obara H., and Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 349 (1998) 317-324
50. De La Garza R.I., and Asnis G.M. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res 977 (2003) 70-79
51. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., and Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7 (2002) 468-473